Clopidogrel for reduction of atherosclerotic events

Article Abstract:

The FDA has approved clopidogrel (Plavix) for use in preventing heart attack, strokes and other conditions caused by abnormal blood clotting. The drug prevents blood platelets from sticking together, which is one of the steps in the formation of a blood clot. In a controlled trial covering 19,185 patients, the drug was slightly more effective than aspirin in preventing heart attacks and strokes. The most common side effects are rash, diarrhea and abdominal pain. The drug is much more expensive than aspirin but cheaper and safer than ticlopidine.

Product/Service Evaluation, Plavix (Medication)

---

Lepirudin for heparin-induced thrombocytopenia

Article Abstract:

The FDA has approved a drug that inhibits thrombin, which is involved in producing blood clots. Lepirudin, which is marketed under the name Refludan, can be used to prevent blood clotting in patients with heparin-induced thrombocytopenia. This complication of heparin treatment damages blood vessels, increasing the risk of life-threatening blood clots. The drug is derived from hirudin, a chemical found in leeches that prevents blood clots. The drug increases the risk of bleeding and should not be used in some patients.

Product introduction, Prevention, Blood clotting, Blood coagulation, Refludan (Medication)

---

Recombinant interleukin-11 for chemotherapy-induced thrombocytopenia

Article Abstract:

The FDA has approved recombinant human interleukin-11 to treat thrombocytopenia in cancer patients. Thrombocytopenia is a drop in the number of blood platelets, which are crucial for clot formation. It is often caused by chemotherapy. Sold under the trade name Neumega, recombinant human interleukin-11 increases the production of blood platelets. This should eliminate the need for platelet transfusions in these patients. The drug can cause side effects such as swelling, shortness of breath, and arrhythmias.

Health aspects, Interleukin-11

Similar abstracts:

• Abstracts: Infection control recommendations for the dental office and the dental laboratory. Dental clinical attire and infection-control procedures: patients' attitudes
• Abstracts: Two new retinoids for psoriasis. Quetiapine for schizophrenia. Topical penciclovir for herpes labialis
• Abstracts: Preparing a proposal for clinical audit. Networking for career planning
• Abstracts: Chlamydial Infections and the Risk of Ectopic Pregnancy. Chlamydia trachomatis genital infections - United States, 1995
• Abstracts: Can clinical interventions change care at the end of life? Remembering the real questions. Opening the black box: how do physicians communicate about advance directives?

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.